Ertugliflozin: Cardioprotective Effects on Epicardial Fat

Stanford University

Status and phase: Completed; Early Phase 1

Conditions: Insulin Resistance; Cardiovascular Diseases; Type 2 Diabetes; Atherosclerosis

Treatments: Drug: Ertugliflozin

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04167761

52647

Details and patient eligibility

About

The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.

Enrollment: 61 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patient at Stanford Cardiovascular Surgery clinic who is scheduled for cardiac bypass surgery or vascular surgery
• history of Diabetes Mellitus Type 2 currently diet controlled, or on metformin or dpp4 inhibitors

Exclusion criteria

• allergy or intolerance to interventional medication
• currently taking insulin, glp-1 inhibitors, or sulfonylureas

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

61 participants in 1 patient group

Ertugliflozin (treated tissue)

Experimental group

Description:

Adipose tissue samples collected from participants were treated with Ertugliflozin at a concentration of 25 µM in vitro. Tissue samples were incubated with Ertugliflozin to evaluate its effects on lipolysis, inflammation, and gene expression in epicardial, pericardial, and subcutaneous adipose tissues

Treatment:

Drug: Ertugliflozin